Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?


Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 09.02.12 in Vol 14, No 1 (2012): Jan-Feb

This paper is in the following e-collection/theme issue:

    Original Paper

    Online Availability and Safety of Drugs in Shortage: A Descriptive Study of Internet Vendor Characteristics

    1Institute of Health Law Studies, California Western School of Law, San Diego, CA, United States

    2San Diego Center for Patient Safety, Department of Anesthesiology, University of California, San Diego - School of Medicine, San Diego, CA, United States

    3Joint Doctoral Program in Global Health, University of California, San Diego - San Diego State University, San Diego, CA, United States

    Corresponding Author:

    Bryan A Liang, MD, JD, PhD

    Institute of Health Law Studies

    California Western School of Law

    350 Cedar Street

    San Diego, CA, 92101

    United States

    Phone: 1 619 515 1568

    Fax:1 619 515 1599



    Background: Unprecedented drug shortages announced by the US Food and Drug Administration (FDA) have severely affected therapeutic access, patient safety, and public health. With continued shortages, patients may seek drugs online.

    Objective: To assess the prevalence of online marketing for current FDA shortage drugs and potential patient safety risks.

    Methods: We performed a descriptive study of the prevalence of online marketing for shortage drugs—that is, offers for sale of each drug, including characteristics of online drug sellers and intermediary sites marketing these drugs.

    Results: Of the 72 FDA shortage-listed drugs, 68 (94%) were offered for sale online. We found 291 offers for these drugs, the vast majority (n = 207, 71.1%) by online drug sellers selling direct to consumers. Intermediary sites included data aggregators (n = 22, 8%), forum links (n = 23, 8%), and personal page data links (n = 34, 12%), as well as Flickr social media links (n = 5, 2%), all advertising drugs without a prescription. Of the 91 online drug sellers identified, 31 (34%) had more than 1 shortage drug offered for sale, representing most (n = 148, 71%) of all online drug seller sales offers. The majority of these online drug sellers (n = 21, 68%) were on the National Association of Boards of Pharmacy (NABP) Not Recommended Sites list. Finally, for shortage drugs with an online drug seller (n = 58, 85%), 53 (91%) had at least one site on the Not Recommended list and 21 (36%) had only sites on the Not Recommended list.

    Conclusions: FDA shortage drugs are widely marketed over the Internet. Suspect online drug sellers and intermediaries dominate these sales offers. As a critical risk management issue, patients, providers, and policymakers should be extremely cautious in procuring shortage drugs through Internet sourcing.

    J Med Internet Res 2012;14(1):e27




    The US Food and Drug Administration (FDA), the American Hospital Association, and the American Society of Health-System Pharmacists have announced a growing crisis of drug shortages in critical areas such as cancer therapy, urgent care, infectious disease, hypertension, orphan disease, pediatric, and other key patient and disease treatment categories [1-6]. According to the Premier healthcare alliance, over the last 6 months of 2010, 89% of providers experienced shortages that may have caused a medication safety issue or error in patient care, 80% experienced shortages that resulted in a delay or cancellation of a patient care intervention, and 98% experienced shortages that resulted in increased costs [7]. A survey by the American Hospital Association found similarly dramatic results, including 99.5% of surveyed hospitals reporting a drug shortage in the prior 6 months and 41% reporting shortages of more than 21 medicines during the same time frame [3].

    This crisis has hit a critical juncture, with shortages leading to loss of patient lives and gross overpricing. The US Institute of Safe Medication Practices has estimated that 15 patients have died in the span of a mere 15 months because of these drug shortages [8,9]. Beyond patient mortality, hospitals have also been forced to delay treatment or leave patients untreated, in unnecessary pain, or with suboptimal clinical care, leading to complications, adverse events, and increased overall burden and costs for the health care system [3,7].

    The dearth of access to these key drugs has resulted in their being sought outside the traditional drug supply chain at virtually any price and condition. Indeed, Institute of Safe Medication Practices notes that hospitals have turned to the risky secondary or “gray” market (secondary resellers outside of direct drug distribution channels) in an effort to address the drug supply concern [10]. Those entering into these markets have faced markups as high as 4500%, with average markups of 650% and virtually all drugs at least double the normal market price [9,10]. Despite knowledge of risks to drug safety, including counterfeiting, diversion, and substandard and falsified drugs in this market, 12% of hospitals admitted to engaging in these purchases [8]. Documented fakes entering through the gray market include counterfeit cancer, human immunodeficiency virus, and diabetes drugs [8,11,12].

    However, of greatest concern is that, due to publicized profiteering, documented safety concerns, and diminishing availability of drugs in the gray market, patients affected by ongoing shortages may turn to a rapidly growing source: the Internet. However, the sale of drugs by illicit online pharmacies is of great concern, as they are a conduit for questionable therapeutic products for a wide range of treatments and diseases [13].

    Indeed, purchasing drugs online is highly risky [14]. There is a significant criminal element in online drug sales, and the National Association of Boards of Pharmacy (NABP) has reported in its analysis that virtually all (96%) online drug sellers violate safe practices and/or pharmacy laws [15]. Further, there have been documented deaths from drugs obtained online, and the FDA, major national drug regulatory agencies, law enforcement, and the World Health Organization all warn against purchasing pharmaceuticals over the Internet [16-18].

    Yet the challenges of drug supply shortages and exorbitant costs may drive patients in great need to seek drugs online. Given this potential crisis, we examined the availability of drugs subject to shortages on the Internet. We investigated online vendors of identified FDA current drugs in shortage to determine the characteristics of these sellers. Specifically, we examined the prevalence of online drug seller sites and intermediary sites including those sites that sell shortage drugs direct to patients, sites that act as intermediaries for the purchase of drugs and market online drug seller sites, and user-generated content via forums and social media that link to online drug sellers. We also determined whether sellers were accredited by the NABP’s Verified Internet Pharmacy Practice Sites (VIPPS) accreditation program, the only accredited online pharmacies recommended by the FDA [19]. This included determination of whether vendors were on the NABP Not Recommended Sites list. Not Recommended sites are Internet drug sellers that appear out of compliance with state and federal laws or NABP patient safety and pharmacy practice standards [20]. Finally, we also assessed characteristics that could have an impact on availability or legitimacy of product, such as “international” status, which have been identified as a suspect characteristic [21]. We did not compare prices or evaluate purchasing requirements, including validating whether sellers required prescriptions, because of ethical and legal concerns arising from fictitious claims of being a patient with a particular disease, and because recent work found that online drug sellers that purportedly “require” prescriptions in fact do not require them, use “surveys” in lieu of prescriptions, and/or illicitly sell prescriptions to purchasers [14,22]. Hence, the potential quality and safety of identified sites can be better determined by examining VIPPS accreditation or Not Recommended status as outlined above. These characteristics are also important in the context of the limited ability of consumers to identify suspect drug-selling websites [23].

    We also did not assess location of website registration or purported sourcing (other than as international or domestic), as these have been found to be forensically difficult to rely upon for assessment of risk characteristics [14]. For example, websites listed in Canada have been found forwarding drug orders to Israel and then financial information to Russia, where the credit card transaction was processed, and the pharmaceutical was shipped from India to a consumer in the United States. Another operated a drug-selling scheme that had its domain name hosted in Korea and registered in St Kitts, with orders dispatched from Oklahoma City [14,24,25]. Other even more dramatic examples include a seller with a Web address in Russia, server in China, payee for the credit card charge in the United Kingdom, payment processing in Australia, and product mailed from Chicago, using a return address of an unsuspecting customer of the drug website; and an Internet drug seller in Costa Rica, with computer servers located in Cyprus, credit card payments processed in Israel, and revenues placed back in bank accounts in Cyprus [26]. As well, many online drug seller websites are mirror or affiliate sites—that is, duplicate selling pages that do not sell the product itself, but instead provide the main website with greater Web presence, with the mirror or affiliate site obtaining a percentage of sales [14]. There is no requirement generally for mirror sites to be located in the same geographic area as the main website.


    We first identified the FDA current shortages list of drugs with an endpoint of September 23, 2011, which included 72 drugs (shortage drugs) [27]. For each identified shortage drug, we searched Google using the search term buy [drug] where drug was the name of the specific shortage drug. Standard security settings were used in the browser, and no user was signed into the browser settings. We then identified the first 5 offers for sale or, if there were fewer than 5 sales offers, the number of sales offers within the first 5 search result pages. We used 5 sales offers as our number of hits to examine based on previous research that found that consumers purchasing goods online visit 3–5 websites prior to purchase [28,29]. For this analysis, we excluded wholesalers and sponsored links. Searches were performed from October 1, 2011 to October 17, 2011.

    Internet sales offers were characterized in two categories. The first identified websites as online drug sellers (direct vendors of the shortage drug selling direct to consumers). Online drug sellers are sometimes called Internet pharmacies or online pharmacies, but since many if not most are in fact not pharmacies [15,20], we have not adopted this term. The second category identified intermediary sites (websites that did not engage in the direct sale of drugs online, but acted as intermediaries or sources of information to purchase shortage drugs online). These included data aggregators (sites collecting data links for a particular shortage drug that links to online drug sellers); forum links (Internet discussion forums with links to online drug sellers); personal page data links (PPDLs, pages of personally placed links, materials, and other information that links to online drug sellers); and other social media links (eg, Facebook or Twitter).

    For each identified online drug seller selling a shortage drug, we assessed whether the site was accredited by the NABP VIPPS program through review of the NABP VIPPS program website. We also assessed whether the online pharmacy was on the NABP Not Recommended Sites list, similarly reviewing the NABP Not Recommended Sites list on the NABP website [20]. We further assessed whether these online pharmacies were internationally or domestically based, regardless of their actual presence or ultimate location, as “international” status is a widely recognized characteristic of potential safety and quality concerns [21].

    Finally, for intermediary sites, we assessed whether links advertised “no-prescription” drugs, an inherent indication of patient and drug safety risk as well as a violation of US law. Note that we did not include the term no prescription when searching for shortage drug advertisers. Non-VIPPS-accredited, international online drug sellers and intermediary sites linking to sites with no-prescription sales were deemed suspect sites.


    We identified 72 shortage drugs (Table 1). When searched, 68 (94%) of these drugs were being advertised online. For these 68 shortage drugs, 291 total offers for sale resulted from online searches, the vast majority (n = 207, 71.1%) by online drug sellers selling direct to consumers. Intermediary sites advertising sales of drugs in shortage included data aggregator sources (n = 22, 8%), forum links (n = 23, 8%), and PPDLs (n = 34, 12%). We also identified Flickr social media links (n = 5, 2%). All intermediary sites and Flickr social media links sales offers (n = 84, 29%) advertised drug sales without a prescription. In total, there were 91 individually identified online drug sellers, 17 forum link sources, 11 Data Aggregators, 16 PPDL sources, and 5 Flickr links. These were coded using alphanumeric designators and are listed in Table 1.

    Most (n = 53, 58%) of the online drug sellers appeared to be of international origin, with Canada being the top purported source of these vendors (n = 32, 60%). We also found one online drug seller (online drug seller CB, Table 2) using the VIPPS accreditation seal, but the seller was not found on the VIPPS accreditation list. We also found one forum link also using an unauthorized VIPPS seal (see Figure 1).

    Several online drug sellers dominated offers for shortage drugs (Table 2). Of the 91 vendors, 31 (34%) offered multiple (>1) drugs in shortage for sale, and were overrepresented with 148 (71%) of all online drug seller marketing events. Of these 31 sellers, 21 (68%) were on the NABP Not Recommended Sites list; 8 (26%) had no information available; only 1 (3%) was VIPPS accredited.

    Finally, of the 68 drugs that were being offered for sale online, 58 (85%) were advertised for sale by at least one online drug seller (Table 1). Among these 58 drugs with online drug sellers, 53 (91%) were offered for sale by at least one Not Recommended NABP site. Indeed, 21 (36%) of these shortage drugs were advertised for sale only by NABP Not Recommended sites (Table 3). Only 4 drugs (7%) had any sales offers from a VIPPS-accredited pharmacy. We also found one shortage drug being advertised as over-the-counter when it is not (calcitriol; Figure 2). We also found other nonshortage drugs to be advertised as over-the-counter when they were not (eg, insulin or vaccines), as well as medical devices (eg, intrauterine devices).

    Table 1. US Food and Drug Administration Current Drug Shortages list and Internet sellers (September 23, 2011)
    View this table
    Figure 1. Unauthorized uses of Verified Internet Pharmacy Practice Sites (VIPPS) seal.
    View this figure
    Figure 2. Shortage drug calcitriol injection advertised as an over-the-counter drug.
    View this figure
    Table 2. Characteristics of Internet shortage drug sellers
    View this table
    Table 3. US Food and Drug Administration Current Drug Shortage list drugs found only on National Association of Boards of Pharmacy’s Not Recommended online drug seller sites
    View this table


    Patients face considerable risks when attempting to procure FDA current shortage drugs online. We find that suspect vendors populate much of the online market for these drugs, and international online drug sellers identified by NABP as Not Recommended dominate this eHealth landscape. With more than 90% of these drugs being offered for sale by at least one NABP Not Recommended site, in effect if an online drug seller is selling an FDA shortage drug, there is virtually always an NABP Not Recommended site selling in that market. Indeed, with more than a third of all of these drugs, including cancer, emergency, orphan drug, and other lifesaving therapeutic products, being sold by only NABP Not Recommended site vendors, it is highly likely that anyone searching online for drugs in shortage will encounter a suspect seller. Even those patients who may seek to legally procure a shortage drug online with a valid prescription may have a difficult time in identifying a legitimate online drug seller source, given oversaturation of suspect providers and marketing sources. This is of great patient safety concern, particularly in the context that most online drug sellers are suspect and research indicating that online drug sellers magnify positive aspects of online purchases but minimize discussion of associated risks [30].

    In addition, with 100% of the intermediary sites marketing these scarce medications as no-prescription drugs (see Figure 3), including social media sites such as Flickr that had been previously unobserved (see Figure 4) [29], this further indicates that the online marketplace for these treatments is extremely risky and diversifying.

    These findings, in combination with previous work showing the extensive presence of illicit online drug sellers in other social media such as Facebook and Twitter [31,32], should place all stakeholders on alert about the legitimacy of online drug sellers, other vendors, and the quality of their products.

    It is particularly troubling that so few NABP VIPPS-accredited pharmacies appeared in the returns from a common Google search. Even if legitimate pharmacies are marketing shortage drugs, the overwhelming presence of NABP Not Recommended online drug sellers may crowd out their arising early or at all in search results. The tremendous dominance of suspect online drug sellers and the virtual absence of authorized VIPPS-accredited online pharmacies for drugs in short supply may have an immediate impact on patient safety. This is particularly true in the context of other work reporting similar findings for online availability of biologics in short supply, which also include absence of VIPPS-accredited vendors, as well as unauthorized use of the VIPPS seal and online drug seller marketing of shortage vaccines as over-the-counter drugs [31].

    In addition, drug shortages, documented and publicized safety risks, and sales profiteering by gray market wholesalers not only may lead patients to attempt to procure shortage drugs through the Internet, but also may lead some providers to seek out shortage drug treatments from these online vendors. Not only is online purchasing from these vendors inherently dangerous, with compromised and counterfeit medications injuring and killing unsuspecting patients globally [13], but also scarcity in the legitimate market questions the very premise that these online drug sellers are selling authentic medication. Given current market-based demands and shortages, it does not appear that online drug sellers would have such an abundant supply of shortage drugs as advertised, and health care providers should regard these offers as highly suspect.

    Indeed, even if these shortage drugs were authentic, Not Recommended online drug sellers, particularly international-based sites highly prevalent in this study, would be unlikely to have adequate knowledge and impetus to ensure proper transport [8]. Many of these drugs, including biologics, are sensitive and require special temperature controls and handling to retain therapeutic effectiveness—quality concerns that may not be known or of concern to suspect vendors [10,31]. Previous reports have also noted issues with online drug sellers’ storage and transport of sensitive drugs [33,34].

    The dominance of international online sellers should be of particular concern, as the FDA does not permit personal drug importation from international sites due to its lack of ability to control quality and oversight of foreign materials [35]. Importing these drugs through purchase from these online drug sellers consequently violates the US Food, Drug, and Cosmetic Act [35]. Further, an argument for importation under an FDA personal importation exemption is inapplicable, even for the vast majority of these drugs, since it generally requires both that the drug be commercially unavailable in the United States and that use of any approved importation be medically supervised [36].

    Moreover, it should also be noted that, from the patient’s perspective, drugs purchased from nondomestic sources are not eligible for public program reimbursement. Such purchases may lead to unnecessary patient expenditures, including remediation expenditures for additional care [36].

    This online environment with its limited regulation and cloaked nature as reviewed by Orizio et al [37], combined with the current drug shortage, is placing tremendous strain on the safety of the drug supply and fueling illicit activity. This situation exploits the desperate nature of vulnerable patients seeking any treatments that could potentially influence the course of their disease, similar to the Laetrile frauds for cancer treatments from the 1970s [26,38]. With the addition of reports that hospitals are increasingly sourcing drugs in shortage from the gray market [8,9], providers and patients seeking these therapies are surrounded by safety threats.

    In response, at a minimum, risk management approaches should be considered. The US Customs and Border Protection agency is overwhelmed in attempting to monitor incoming drugs. It cannot destroy contraband suspect drugs coming through the mails due to international postal conventions. In general, it is limited to returning the package and contents to the original sender (for potential illicit resale) if not assessed within 24 hours, or simply allowing it to be sent on for delivery[14,39-41]. Hence, demand-side actions should be a focus.

    Figure 3. Intermediary site marketing products as no-prescription drug.
    View this figure
    Figure 4. Flickr social media link for no-prescription shortage drug.
    View this figure

    Providers seeking drugs in short supply should verify the authenticity of the drug pedigree (ie, its documentation of transport) and should take advantage of professional resources for safe sourcing of drugs [10,42]. This includes implementing facility safety and regulatory protocols ensuring drug sourcing through accredited wholesalers and vendors that can and do certify that they procure drugs from legitimate, accredited distributors in compliance with pharmaceutical distributor laws, licensure, and regulations. NABP also provides accreditation here, and providers should purchase only from these NABP-accredited vendors [43].

    This approach of listing and updating legitimate wholesale sources of drugs by a neutral, trusted entity should be considered as a strategy more broadly to allow rapid determination of vendor legitimacy on regional levels globally. These regional entities can then share information as to identified problematic vendors for information coordination, as well as determining and communicating best practices in promoting safety measures in the drug supply chain.

    Patients should also be counseled about the dangers of counterfeit and substandard drugs when purchasing drugs online, and be advised to purchase only from verified NABP VIPPS-accredited online drug sellers as recommended by the FDA [16]. They should also be encouraged to inquire about provider drug-procurement policies, and require that drugs administered to them have appropriate pedigree evidencing authenticity. The patient is the last barrier to harm and should be partnered with and actively engaged in patient safety efforts. Such an approach is amenable to application in other health-delivery environments as well, with consistent public health messages and patient education such as that promulgated by important global health groups such as the International Council of Nurses [44]. These public health messages should expressly note global drug regulatory authority warnings and updated information on the dangers of purchasing drugs—including shortage drugs—online [18,19].

    These drug shortages have historically been a problem in clinical care, and have been the subject of past calls for reform and attention due to their adverse impact on public health [10,45-48]. Indeed, drug shortages have tripled in the last 6 years, while few have left the list, portraying a worrying trend [3], while the global nature of the problem has become increasingly dire [49,50].

    Beyond reactive approaches, organized, proactive planning by stakeholders to address this issue should be started as soon as possible. Existing calls for enhanced drug regulatory authority powers to address drug shortages, stronger regulation of pharmaceutical distribution and pricing incentives, and more stringent penalties against illegal profiteering activities should be supported by stakeholders’ joining together in public–private partnership models to plan for new challenges in pharmaceutical supplies and safety.

    These public–private partnerships should include multisector engagement with pharmaceutical manufacturers (including both brand and generic industries), drug regulators, patient safety and advocacy groups, hospitals, group purchasing organizations, and professional societies to prioritize and develop organized responses to drug shortages. Domestic and regional best practices can be applied in proactive efforts as well, with shared systems planning and strategies among stakeholders integrated across geopolitical and health-delivery environments. At the outset, a risk management approach may be best for priority planning—for example, public–private partnerships organized around supplying chemotherapy drugs and emergency department treatments, whose absence may have the greatest potential adverse clinical impact. In addition, due to the security threat illegal pharmaceutical sales pose and the need to address drug shortages as a national emergency, national security agencies and legal authorities should also be included in these public–private partnerships.

    Integrated industry, regulator, patient, and provider partnerships would be able to better anticipate potential shortages and their impact on patient safety, and to help develop information resources and responses for stakeholders that are currently lacking for these situations [51]. Further, these partnerships would enhance existing calls for more advanced notification of shortages by manufacturers through establishing lines of communication [3,47,52,53] and would help to develop market-based incentives to encourage investment in manufacturing of shortage drugs, such as reimbursement-rate adjustment and creative financing for increased production [6,54].

    Finally, strategic plans for safe substitutions of shortage drugs that could be integrated into emergency planning for regional delivery systems, along with voluntary international coordination of emergency supplies, should be considered in particularly needed areas and populations (such as public health treatments for pandemics or other communicable disease events). These partnerships would be similar to local coalition efforts to reallocate drugs subject to shortages by borrowing, back-ordering, increasing surveillance and legal enforcement against potential counterfeits, and seeking safe alternative supply sources through greater regional coordination [8,33].

    We note that this study has several limitations. It evaluates the drugs on the FDA Current Drug Shortages list as of one point in time, and its assessment of online availability similarly is limited to that period. Further, websites arise, change, and are taken down dynamically on the Internet, so the information and websites found in this study are necessarily limited as well. NABP VIPPS-accredited online pharmacies and NABP Not Recommended site designations also are limited in validity over time due to changes in the Internet and vendors. Finally, we did not determine the actual quality of products through test purchasing, as buying drugs for a fictional patient raises ethical and legal concerns.

    Overall, drugs on the FDA Current Drug Shortages list are critical therapeutic tools in the medical arsenal. Because of the crisis of access to these drugs, sources such as the Internet may be considered convenient for procurement. However, suspect vendors appear to dominate online marketing of shortage drugs. This high-risk digital conduit of medicines should be addressed. Reactive and proactive risk management strategies should be engaged to ensure that providers render optimal, safe care to patients, and that patients who are considering purchasing online due to desperate circumstances do not become the next victims of the drug shortage. Extreme caution and caveat emptor may best describe the themes when approaching this eHealth market.


    BAL presented this work in part at the Global Drug Safety Roundtable, Council on Foreign Relations, December 5, 2011, and thanks that audience for useful comments. TKM is the 2011–2012 Carl L. Alsberg, MD, Fellow of the Partnership for Safe Medicines, the latter of which is not connected with the submitted work, and gratefully acknowledges that support.

    Conflicts of Interest

    None declared.


    1. Kaiser J. Medicine. Shortages of cancer drugs put patients, trials at risk. Science 2011 Apr 29;332(6029):523. [CrossRef] [Medline]
    2. Emanuel EJ. The New York Times. 2011 Aug 6. Shortchanging Cancer Patients   URL: http:/​/static.​​external_content/​untrusted_dlcp/​​en/​us/​doubleclick/​pdfs/​DoubleClick-02-2005-Search-Before-the-Purchase.​pdf [accessed 2011-12-16] [WebCite Cache]
    3. Mitka M. FDA, US hospital and pharmacy groups report drug shortages a growing problem. JAMA 2011 Sep 14;306(10):1069-1070. [CrossRef] [Medline]
    4. Anonymous. Shortages of cancer drugs in the USA. Lancet Oncol 2011 Apr;12(4):313. [CrossRef] [Medline]
    5. Dolgin E. NIH faces marching orders on orphan drug shortage. Nat Med 2011 May;17(5):522. [CrossRef] [Medline]
    6. Roehr B. FDA is to hold public meeting to discuss reasons for drug shortages. BMJ 2011;343:d5650. [Medline]
    7. Cherici C, Frazier J, Feldman M, Gordon B, Petrykiw C, Russel W, et al. Premiere Inc. 2011 Mar. Navigating Drug Shortages in American Healthcare: A Premier Healthcare Alliance Analysis   URL: [accessed 2011-11-16] [WebCite Cache]
    8. Institute for Safe Medication Practices. 2011 Aug 25. Gray Market, Black Heart: Pharmaceutical Gray Market Finds a Disturbing Niche During the Drug Shortage Crisis   URL: [accessed 2011-11-16] [WebCite Cache]
    9. Johnson LA. Yahoo! News. 2011 Sep 24. AP IMPACT: Hospital Drug Shortages Deadly, Costly.   URL: [accessed 2011-11-16] [WebCite Cache]
    10. Cherici C, McGinnis P, Russell W. Premier Inc. 2011 Aug. Buyer Beware: Drug Shortages and the Gray Market   URL: [accessed 2011-11-16] [WebCite Cache]
    11. Kane J. PBS Newshour. 2011 Aug 29. Drug Prices Soar as Hospital Suppliers are Forced into 'Gray Market'   URL: http:/​/www.​​newshour/​rundown/​2011/​08/​drug-prices-soar-as-pharmacists-are-forced-into-gray-market.​html [accessed 2011-11-16] [WebCite Cache]
    12. Clarke PE. US Food and Drug Administration. 2011 Jun 9. FDA Working to Lessen Patient Impact from Drug Shortages   URL: [accessed 2011-11-16] [WebCite Cache]
    13. Mackey TK, Liang BA. The global counterfeit drug trade: patient safety and public health risks. J Pharm Sci 2011 Nov;100(11):4571-4579. [CrossRef] [Medline]
    14. Liang BA, Mackey T. Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. Am J Law Med 2009;35(1):125-184. [Medline]
    15. National Association of Boards of Pharmacy. 2011 Jul 28. NABP Issues Rogue Online Pharmacy Public Health Alert   URL: [accessed 2011-11-16] [WebCite Cache]
    16. US Food and Drug Administration. 2011 Oct 19. The Possible Dangers of Buying Medicines over the Internet   URL: [accessed 2011-11-16] [WebCite Cache]
    17. US Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Consumer Alert: Prescription Drugs: Buying On-line Could Mean Doing Time   URL: [accessed 2011-11-16] [WebCite Cache]
    18. World Health Organization. 2010 Jan. Medicines: Spurious/Falsely-Labelled/Falsified/Counterfeit (SFFC) Medicines   URL: [accessed 2011-11-16] [WebCite Cache]
    19. US Food and Drug Administration. What Can I Do to Help Ensure I Do Not Receive or Take Counterfeit Medicine? 2010 Dec 14   URL: [accessed 2011-11-16] [WebCite Cache]
    20. National Association of Boards of Pharmacy. 2012. Not Recommended Sites   URL: [accessed 2011-11-16] [WebCite Cache]
    21. National Association of Boards of Pharmacy. 2012. VIPPS: Set Yourself Apart From Rogue Sites   URL: [accessed 2011-11-16] [WebCite Cache]
    22. Griffin G. CNN. 2009 Feb 2. CNN Special Investigation Report: Illegal Online Pharmacies   URL: [accessed 2011-12-16] [WebCite Cache]
    23. Orizio G, Schulz P, Domenighini S, Bressanelli M, Rubinelli S, Caimi L, et al. Online consultations in cyberpharmacies: completeness and patient safety. Telemed J E Health 2009 Dec;15(10):1022-1025. [CrossRef] [Medline]
    24. Work D. Winston-Salem Journal. 2009 Feb 7. Phony Medicines Available Online: Bogus Pharmacies on Internet Spread Drugs That Can Be Dangerous, Deadly   URL: [accessed 2011-12-17] [WebCite Cache]
    25. Jackson G. Faking it: the dangers of counterfeit medicine on the internet. Int J Clin Pract 2009 Feb;63(2):181. [CrossRef] [Medline]
    26. Liang BA. A dose of reality: promoting access to pharmaceuticals. Wake Forest Intellect Prop Law J 2008;8(3):301-386.
    27. US Food and Drug Administration. 2011 Nov 16. Current Drug Shortages   URL: [accessed 2011-11-16] [WebCite Cache]
    28. Ahuja M, Gupta B, Raman P. An empirical investigation of online consumer purchasing behavior. Commun ACM 2003 Dec;46(12):145. [CrossRef]
    29. 2005 Feb. Search Before the Purchase   URL: http:/​/static.​​external_content/​untrusted_dlcp/​​en/​us/​doubleclick/​pdfs/​DoubleClick-02-2005-Search-Before-the-Purchase.​pdf [accessed 2011-11-16] [WebCite Cache]
    30. Orizio G, Rubinelli S, Schulz PJ, Domenighini S, Bressanelli M, Caimi L, et al. "Save 30% if you buy today". Online pharmacies and the enhancement of peripheral thinking in consumers. Pharmacoepidemiol Drug Saf 2010 Sep;19(9):970-976. [CrossRef] [Medline]
    31. Liang BA, Mackey TK. Vaccine shortages and suspect online pharmacy sellers. Vaccine 2012 Jan 5;30(2):105-108. [CrossRef] [Medline]
    32. Liang BA, Mackey TK. Prevalence and Global Health implications of social media in direct-to-consumer drug advertising. J Med Internet Res 2011;13(3):e64 [FREE Full text] [CrossRef] [Medline]
    33. Weiss AM. Buying prescription drugs on the internet: promises and pitfalls. Cleve Clin J Med 2006 Mar;73(3):282-288 [FREE Full text] [Medline]
    34. Orizio G, Schulz P, Domenighini S, Caimi L, Rosati C, Rubinelli S, et al. Cyberdrugs: a cross-sectional study of online pharmacies characteristics. Eur J Public Health 2009 Aug;19(4):375-377 [FREE Full text] [CrossRef] [Medline]
    35. Liang BA. Fade to black: importation and counterfeit drugs. Am J Law Med 2006;32(2-3):279-323. [Medline]
    36. Cooperman T, Lewitt G. Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. Am J Law Med 2009;35(4):682-3; author reply 683-90. [Medline]
    37. Orizio G, Merla A, Schulz PJ, Gelatti U. Quality of online pharmacies and websites selling prescription drugs: a systematic review. J Med Internet Res 2011;13(3):e74 [FREE Full text] [CrossRef] [Medline]
    38. Schulte G. An overview of pharmaceutical smuggling cases in San Diego: it goes better when agencies work together. J Biolaw Bus 2006;9(4):41-45.
    39. Federal Food, Drug, and Cosmetic Act, 21 USC §381(a) (2000).   URL: http:/​/www.​​RegulatoryInformation/​Legislation/​FederalFoodDrugandCosmeticActFDCAct/​FDCActChapterVIIIImportsandExports/​ucm107032.​htm [accessed 2012-01-31] [WebCite Cache]
    40. Anonymous. Hearing on Refusal of Admission, 21 CFR §1.94 (2008).   URL: [accessed 2012-01-31] [WebCite Cache]
    41. Stana RM. US Government Accountability Office. 2005. Prescription Drugs: Enhanced Efforts and Better Agency Coordination Needed to Address Illegal Importation: Testimony Before the Subcommittee on Oversight and Investigations, 109th Cong. 33 ()   URL: [accessed 2011-12-17] [WebCite Cache]
    42. Anonymous. Partnership for Safe Medicines. 2011. L.E.A.D.E.R.’s Guide For Pharmacists   URL: [accessed 2011-11-16] [WebCite Cache]
    43. National Association of Boards of Pharmacy. 2011 Nov 16. VAWD-Accredited Facilities   URL: [accessed 2011-11-16] [WebCite Cache]
    44. International Council of Nurses. 2010 May 12. 2005 Counterfeits Kill: Nurses Target Counterfeit Medicines   URL: [accessed 2011-12-17] [WebCite Cache]
    45. Steinbrook R. Drug shortages and public health. N Engl J Med 2009 Oct 15;361(16):1525-1527. [CrossRef] [Medline]
    46. Charatan F. Prescription drug shortages plague US. BMJ 2001 Jan 20;322(7279):130. [Medline]
    47. Hampton T. Experts look for ways to lessen impact of drug shortages and discontinuations. JAMA 2007 Aug 15;298(7):727-728. [CrossRef] [Medline]
    48. Jensen V, Rappaport BA. The reality of drug shortages--the case of the injectable agent propofol. N Engl J Med 2010 Aug 26;363(9):806-807 [FREE Full text] [CrossRef] [Medline]
    49. Health Canada. 2011 Nov 21. Web info sheet on Drug Shortages   URL: [accessed 2011-12-17] [WebCite Cache]
    50. Generics and Biosimilars Initiative. 2011 Nov 18. Biosimilars and Cancer Drug Shortages in Europe   URL: [accessed 2011-12-17] [WebCite Cache]
    51. Kaakeh R, Sweet BV, Reilly C, Bush C, DeLoach S, Higgins B, et al. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm 2011 Oct 1;68(19):1811-1819. [CrossRef] [Medline]
    52. Thompson CA. House legislation proposes early warning system for drug shortages. Am J Health Syst Pharm 2011 Aug 1;68(15):1379-1381. [CrossRef] [Medline]
    53. Barlas S. Severe drug shortages impose heavy costs on hospital pharmacies: senate bill might help … or not. P T 2011 May;36(5):242-302. [Medline]
    54. Connelly P, Quinn BP. Manufacturing decline yields drug shortages. Science 2011 Jul 8;333(6039):156-157. [CrossRef] [Medline]


    FDA: Food and Drug Administration
    NABP: National Association of Boards of Pharmacy
    PPDL: personal page data link

    Edited by G Eysenbach; submitted 16.11.11; peer-reviewed by R Levaggi, I Montoya, L Ivanitskaya; comments to author 07.12.11; revised version received 19.12.11; accepted 16.01.12; published 09.02.12

    ©Bryan A Liang, Tim K Mackey. Originally published in the Journal of Medical Internet Research (, 09.02.2012.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on, as well as this copyright and license information must be included.